Drug intelligence / Profile preview

Yiqi Guben Wan

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Yiqi Guben Wan is a traditional Chinese medicine (TCM) formulation that has been investigated for its therapeutic potential, particularly in allergic asthma. Research indicates that it alleviates airway inflammation and remodeling by suppressing the TLR4/NF-κB signaling pathway, leading to reduced expression of key inflammatory mediators. Additionally, it has been shown to improve mitochondrial dysfunction, which contributes to its overall therapeutic effects in respiratory conditions.

Other names: YiQi GuBen formulaYiQi GuBen capsuleYQGB益气固表丸模拟剂

Targets

MYD88 (Myeloid differentiation primary response protein MyD88)NFKBIA (NFKB inhibitor alpha)PPARGC1A (Peroxisome proliferator–activated receptor gamma coactivator 1-alpha)RELA (Nuclear Factor Kappa B Subunit p65)TRAF6TLR4 (Toll-like receptor 4)TFAM (Mitochondrial transcription factor A)

Beyond the preview

Go deeper on Yiqi Guben Wan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yiqi Guben Wan.